Ethyol

Ethyol is a brand name of amifostine, approved by the FDA in the following formulation(s):

ETHYOL (amifostine - injectable; injection)

• 
  Manufacturer: MEDIMMUNE
  
  Approval date: December 8, 1995
  
  Strength(s): 500MG/VIAL ^[RLD][AP]

Has a generic version of Ethyol been approved?

A generic version of Ethyol has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ethyol and have been approved by the FDA:

amifostine injectable; injection

• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: March 14, 2008
  
  Strength(s): 500MG/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ethyol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Crystalline amifostine compositions and methods of the preparation and use of same
  Patent 5,424,471
  Issued: June 13, 1995
  Inventor(s): Kennedy; Paul E. & Rajewski; Roger A. & Baldoni; John M.
  Assignee(s): U.S. Bioscience, Inc.
  The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.
  
  Patent expiration dates:
  
  
  • July 31, 2012
    
  
  



• 
  Crystalline amifostine compositions
  Patent 5,591,731
  Issued: January 7, 1997
  Inventor(s): Kennedy; Paul E. & Rajewski; Roger A. & Baldoni; John M.
  Assignee(s): U.S. Bioscience, Inc.
  The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.
  
  Patent expiration dates:
  
  
  • July 31, 2012
    
  
  



• 
  Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
  Patent 5,994,409
  Issued: November 30, 1999
  Inventor(s): Stogniew; Martin & Alberts; David S. & Kaplan; Edward H.
  Assignee(s): U.S. Bioscience, Inc.
  The Arizona Board of Regents on behalf of the University of Arizona
  The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
  
  Patent expiration dates:
  
  
  • December 8, 2017
    
    ✓ 
    Patent use: METHODS FOR USING THE DRUG PRODUCT
  
  

See also...

• Ethyol Consumer Information (Wolters Kluwer)
• Ethyol Advanced Consumer Information (Micromedex)
• Ethyol AHFS DI Monographs (ASHP)
• Amifostine Consumer Information (Wolters Kluwer)
• Amifostine Intravenous Advanced Consumer Information (Micromedex)
• Amifostine AHFS DI Monographs (ASHP)